EHC: Recognizing Von Willebrand Factor as a Critical Medicine in Bleeding Care
The European Haemophilia Consortium (EHC) recently shared a post on X:
”Von Willebrand Disease affects 1:1000 individuals and, if not recognised, may cause severe bleeding symptoms after trauma or surgery that can be life-threatening. It’s time for health systems to recognise Von Willebrand Factor as a Critical Medicine. European Medicines Agency”
Von Willebrand Disease (VWD), the most common inherited bleeding disorder, affects approximately 1 in 1,000 individuals.
When unrecognized or untreated, it can lead to serious, even life-threatening bleeding, particularly after trauma or surgical procedures.
Despite its prevalence and potential severity, VWD remains underdiagnosed and undertreated in many health systems.
There is an urgent need to designate Von Willebrand Factor (VWF) as a Critical Medicine to ensure timely diagnosis, treatment access, and improved outcomes for patients.
Recognizing VWF’s essential role in bleeding management is a key step toward better care for individuals living with VWD worldwide.
Hemostasis Today, your daily update on the waves in bleeding disorders community.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants